GENB (Generate Biomedicines, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings
Generate Biomedicines, Inc. Common Stock (GENB) is a publicly traded the market company. As of May 21, 2026, GENB trades at $13.25 with a market cap of $1.67B and a P/E ratio of -12.06. GENB moved +5.07% today. Year to date, GENB is +0.00%; over the trailing twelve months it is flat. Its 52-week range spans $11.00 to $16.75. Analyst consensus is strong buy with an average price target of $25.40. Rallies surfaces GENB's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Who owns GENB stock?
Hedge funds tracked by Rallies that own GENB include Nvidia Corp and Centerbook Partners. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Generate Biomedicines, Inc. Common Stock.
GENB Key Metrics
Key financial metrics for GENB
Metric
Value
Price
$13.25
Market Cap
$1.67B
P/E Ratio
-12.06
EPS
$-1.07
Dividend Yield
0.00%
52-Week High
$16.75
52-Week Low
$11.00
Volume
827.46K
Avg Volume
0
Revenue (TTM)
$7.22M
Net Income
$-61.71M
Gross Margin
0.00%
Top Hedge Funds Holding GENB
Nvidia Corp holds 833.33K shares of GENB, changed +0.00% as of Mar 31, 2026.
Centerbook Partners holds 266.81K shares of GENB, changed +0.00% as of Mar 31, 2026.
Hedge funds tracked by Rallies that own GENB include Nvidia Corp and Centerbook Partners. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Generate Biomedicines, Inc. Common Stock.
Does Rallies show 13F holders for GENB?
Yes. Rallies tracks hedge fund and 13F ownership data for GENB, including fund names, share counts, latest tracked quarter, and position changes when available.
Is GENB research on Rallies investment advice?
No. Rallies provides research, data, and educational context for GENB. It does not provide personalized investment advice.
